KRAS is one of the most frequently mutated proto-oncogenes in pancreatic ductal adenocarcinoma (PDAC) and aberrantly activated in triple-negative breast cancer (TNBC). This evidence concerns the gene KRAS and pancreatic ductal adenocarcinoma.